http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016529246-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
| filingDate | 2014-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016529246-A |
| titleOfInvention | Method for treating diffuse large B-cell lymphoma (DLBCL) using BET bromodomain inhibitor |
| abstract | A composition comprising a pharmaceutically acceptable amount of a thienotriazolodiazepine compound or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a diffuse large B cell property of an active B cell A method for treating diffuse large B-cell lymphoma comprising administering to a patient having lymphoma, wherein the thienotriazolodiazepine compound is represented by the following formula (1): (In the formula, R 1 is alkyl having 1 to 4 carbon atoms, and R 2 is a hydrogen atom; a halogen atom; or a carbon number of 1 to 4 optionally substituted with a halogen atom or a hydroxyl group. R 3 is a halogen atom; a halogen atom, an alkyl having 1 to 4 carbon atoms, an alkoxy having 1 to 4 carbon atoms, or phenyl optionally substituted with cyano; —NR 5 — ( CH 2) m -R 6 (wherein, R 5 is alkyl having a carbon number of hydrogen atoms or 1 to 4, m is an integer of 0 to 4, R 6 is substituted with a halogen atom Or —NR 7 —CO— (CH 2 ) n —R 8 (wherein R 7 is a hydrogen atom or alkyl having 1 to 4 carbon atoms, n is an integer of 0 to 2, R 8 is . Be substituted with androgenic atom is also phenyl or pyridyl), and, R 4 is, - (CH 2) in a -CO-NH-R 9 (wherein, a is an integer from 1 to 4, R 9 is alkyl having 1 to 4 carbon atoms; hydroxyalkyl having 1 to 4 carbon atoms; alkoxy having 1 to 4 carbon atoms; or alkyl having 1 to 4 carbon atoms; It is phenyl or pyridyl optionally substituted with an alkoxy, amino or hydroxyl group having carbon number.) Or — (CH 2 ) b —COOR 10 (wherein b is an integer of 1 to 4 and R 10 Is an alkyl having 1 to 4 carbon atoms). [Selection] Figure 13 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019535671-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7129973-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11679106-B2 |
| priorityDate | 2013-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 201.